Driehaus Capital Management’s TherapeuticsMD TXMD Stock Holding History

Driehaus Capital Management’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3,605	Closed	-$1.53M	–	605
2016 Q2	$1.53M	Buy	3,605 +2,064	+134%	+$851K	0.05%	294
2016 Q1	$493K	Buy	1,541 +1,153	+297%	+$393K	0.02%	459
2015 Q4	$201K	Buy	+388	New	+$143K	0.01%	498
2015 Q3	–	Sell	-1,189	Closed	-$467K	–	617
2015 Q2	$467K	Buy	+1,189	New	+$420K	0.02%	467

Other funds holding TXMD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Driehaus Capital Management's TXMD Position: Q3 2016 in Review

Driehaus Capital Management sold out of TherapeuticsMD (TXMD) in Q3 2016, closing a stake of 3,605 shares — an estimated $1.53M sold.

Driehaus Capital Management first reported a position in TXMD in Q2 2015 and held it in 4 quarters. The position peaked at $1.53M in Q2 2016. 137 funds tracked by Wall St. Rank hold TXMD as of Q3 2016.

Driehaus Capital Management reported no remaining TherapeuticsMD position as of Q3 2016 after selling out during the quarter.
Driehaus Capital Management sold 3,605 TherapeuticsMD shares in Q3 2016, an estimated $1.53M.
Driehaus Capital Management first reported a position in TherapeuticsMD in Q2 2015 and held it in 4 quarters.
Driehaus Capital Management's TherapeuticsMD position peaked at $1.53M in Q2 2016.
137 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2016.

Based on Driehaus Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.